Press Releases aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2 ^USD	+3.63%		+18.34%	+41.84%

May. 14	ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	CI
May. 02	ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference	May. 15	AQ
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis	May. 14	AQ
ATyr Pharma to Present at Upcoming Investor Conferences	May. 06	AQ
Atyr Pharma: Q1 Earnings Snapshot	May. 02	AQ
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update	May. 02	AQ
ATyr Pharma to Participate in April Investor Conferences	Apr. 01	AQ
Atyr Pharma: Q4 Earnings Snapshot	Mar. 14	AQ
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	Mar. 14	AQ
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	Feb. 28	AQ
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	Feb. 21	AQ
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	Jan. 29	AQ
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor	Jan. 18	AQ
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023	Nov. 13	AQ
Atyr Pharma: Q3 Earnings Snapshot	Nov. 09	AQ
ATyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update	Nov. 09	AQ
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD	Nov. 01	AQ
ATyr Pharma to Present at November Investor Conferences	Nov. 01	AQ
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD	23-10-31	AQ
ATyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes	23-09-11	AQ
ATyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-08-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Press Releases

Filters